PMID- 22704044
OWN - NLM
STAT- MEDLINE
DCOM- 20121026
LR  - 20151119
IS  - 1873-6327 (Electronic)
IS  - 0306-4603 (Linking)
VI  - 37
IP  - 10
DP  - 2012 Oct
TI  - Antidepressant-like effects of ecstasy in subjects with a predisposition to 
      depression.
PG  - 1189-92
LID - 10.1016/j.addbeh.2012.05.022 [doi]
AB  - INTRODUCTION: Positive effects of ecstasy on mood and self-esteem due to 
      increased synaptic serotonin levels may indicate a potential antidepressant-like 
      action. This effect may be more prominent in subjects with a pre-existing mood 
      disturbance who may use ecstasy more frequently as a 'self-medication'. This 
      study compared depressive symptoms and the immediate effects of ecstasy on mood 
      in subjects with (WP) and without (NP) a predisposition to depression. METHODS: 
      Current ecstasy users were assessed using the profile of mood states (POMS) and 
      beck depression inventory (BDI) when drug-free, and during social gathering, when 
      20 subjects voluntarily consumed ecstasy (ecstasy group) and 20 abstained from 
      ecstasy (control group). Predisposition to depression was determined using the 
      Brief Symptom Inventory. During social gathering, POMS and BDI were administered 
      60 min after ecstasy consumption, or at matched time for controls. 
      3,4-Methylenedioxymethamphetamine (MDMA) exposure was confirmed using saliva 
      samples collected 60 min after pill ingestion. RESULTS: There was no difference 
      in ecstasy use patterns between the groups. When drug-free, the WP subjects had 
      greater mood disturbance and depressive symptoms than the NP group (POMS: NP 
      5.85+/-1.63, WP 14.5+/-2.81, p<0.05, BDI: NP 4.9+/-0.86, WP 11.2+/-1.65, p<0.01). During 
      social gathering, WP subjects who consumed ecstasy reported a significant 
      decrease in depressive symptoms (F(1,35)=5.47, p<0.05). CONCLUSIONS: A decrease 
      in depressive symptoms was observed in subjects predisposed to depression. This 
      antidepressant-like action of MDMA may contribute to its use, particularly among 
      people with an existing or latent depressive disorder.
CI  - Copyright (c) 2012 Elsevier Ltd. All rights reserved.
FAU - Majumder, Irina
AU  - Majumder I
AD  - University of South Australia, School of Pharmacy and Medical Sciences, Adelaide, 
      South Australia, Australia. irina.majumder@unisa.edu.au
FAU - White, Jason M
AU  - White JM
FAU - Irvine, Rodney J
AU  - Irvine RJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120606
PL  - England
TA  - Addict Behav
JT  - Addictive behaviors
JID - 7603486
RN  - 0 (Serotonin Agents)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Affect/*drug effects
MH  - Case-Control Studies
MH  - Depressive Disorder/*epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Serotonin Agents/*pharmacology
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2012/06/19 06:00
MHDA- 2012/10/27 06:00
CRDT- 2012/06/19 06:00
PHST- 2011/11/08 00:00 [received]
PHST- 2012/04/24 00:00 [revised]
PHST- 2012/05/31 00:00 [accepted]
PHST- 2012/06/19 06:00 [entrez]
PHST- 2012/06/19 06:00 [pubmed]
PHST- 2012/10/27 06:00 [medline]
AID - S0306-4603(12)00224-9 [pii]
AID - 10.1016/j.addbeh.2012.05.022 [doi]
PST - ppublish
SO  - Addict Behav. 2012 Oct;37(10):1189-92. doi: 10.1016/j.addbeh.2012.05.022. Epub 
      2012 Jun 6.